Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Lung Cancer. 2012 Mar;75(3):269-74. doi: 10.1016/j.lungcan.2011.09.010. Epub 2011 Oct 11.

Is there a standard regimen for first-line treatment of advanced/metastatic Non-Small-Cell Lung Cancer? What has meta-analyses contributed to today's standard of care.

Author information

1
Department of Medical Oncology, University General Hospital of Heraklion, 71110 Heraklion, Crete, Greece. agpallis@gmail.com

Abstract

Despite the fact that Non-Small Cell Lung Cancer (NSCLC) represents the leading cause of cancer-related death in the western, after two decades of intensive clinical research, there still remains a substantial lack of consensus regarding the appropriate chemotherapeutic management of patients with advanced stage disease. For patients with metastatic disease and good performance status, what is considered "standard" treatment is a platinum-based doublet. Several meta-analyses have been performed in order to answer several questionable issues in the treatment of these patients. Their conclusions could be used as an effective instrument for resolving various clinical questions, such as advantage of chemotherapy for advanced NSCLC and identification of the most active combinations and most active agents, or treatment duration and thus providing more reliable evidence for clinical practice.

PMID:
21996086
DOI:
10.1016/j.lungcan.2011.09.010
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center